Cardiac Allograft Vasculopathy

5

Review clinical trials related to Cardiac Allograft Vasculopathy. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation

Cardiac allograft vasculopathy (CAV) is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. Surveillance for CAV is vital; however an ideal approach has not been established. The goal of this study is to assess whether noninvasive positron emission tomography (PET) based surveillance is non-inferior to invasive coronary angiography (ICA) surveillance.

Participants needed: 576
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Ottawa Heart Institute Research CorporationUpdated: May 6, 2026Locations: 5
Eligibility criteria

Post heart transplant 2-10 years. [+2]

Contraindication to dipyridamole due to severe aortic stenosis. [+7]

Status: Recruiting

AERIAL Trial: Antiplatelet Therapy in Heart Transplantation

Cardiac allograft vasculopathy is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. The research team is investigating whether early antiplatelet therapy post heart transplant can prevent the development of CAV. This study will determine the feasibility of a large multicenter randomized placebo-controlled trial to answer this question.

Participants needed: 135
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Ottawa Heart Institute Research CorporationUpdated: May 6, 2026Locations: 3
Eligibility criteria

Heart transplant [+2]

Allergy or known intolerance to aspirin [+11]

Status: Not yet recruiting

Comparing PCCT With ICA and IVUS in Detecting Cardiac Allograft Vasculopathy

In traditional coronary artery disease, patients often experience symptoms such as angina. However, heart transplant patients lack nerve connections in the transplanted heart and therefore usually do not notice any symptoms. For this reason, routine examinations are performed using traditional coronary angiography at one, three, and six years after transplantation, sometimes with the addition of coronary ultrasound. A new technique, photon-counting computed tomography, has now been developed and may potentially replace both traditional coronary angiography and intravascular ultrasound. In this study, we aim to investigate how well this method works in diagnosing coronary artery changes compared to the established methods.

Participants needed: 100
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Sahlgrenska University HospitalUpdated: Jun 13, 2025Locations: 1Duration: 3 Days
Eligibility criteria

Adult heart transplant recipients. [+2]

Contrast allergy [+3]

Status: Recruiting

Physiologic Assessment of Microvascular Function in Heart Transplant Patients

The aim of the study is to evaluate the impact of early microvascular disease assessed by coronary physiologic indices such as fractional flow reserve (FFR), coronary flow reserve (CFR), index of microvascular resistance (IMR) on future occurrence of cardiac allograft vasculopathy (CAV) in heart transplant recipients.

Participants needed: 200
Trial details
Age: 18-85Biological sex: AllType: ObservationalSponsor: Samsung Medical CenterUpdated: Mar 14, 2025Locations: 1Duration: 6 Years
Eligibility criteria

Subject over age of 18 [+1]

Patients with cardiogenic shock [+6]

Status: Recruiting

Microvascular Cardiac Allograft Vasculopathy Trial

The aim of the mCAV study is a comprehensive characterization of the genetic, morphological and functional phenotype of isolated microvascular graft vasculopathy (mCAV) after orthotopic heart transplantation (OHT). The utilized methods include dynamic echocardiography, magnetic resonance imaging, invasive microvascular resistance measurements, histology, cellular calcium-signaling and magnetocardiography as well as molecular genetic expression analysis (miRNA based).

Participants needed: 50
Trial details
Biological sex: AllType: ObservationalSponsor: German Heart InstituteUpdated: Aug 12, 2024Locations: 1
Eligibility criteria

able to consent [+4]

Addiction or other diseases that do not allow the patient to assess the nature a... [+5]